Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
Nvidia and Nike Lead Biggest Wave Yet of Tokenized Stock Objections
02.11.2026 17:36
Nvidia, Costco, Nike and nine other companies objected to trading of their shares on the planned OKX-ICE tokenized stock venue, bringing the total to 50.
Musk Predicts “Banger Drugs Coming Out” from Eli Lilly
02.11.2026 17:11
Key TakeawaysEli Lilly raised its 2026 revenue guidance to $91 billion to $92 billion, its second raise in three months, and Elon Musk backed CEO Dave Ricks on X a day later. Mounjaro and Zepbound made 65% of revenue in the first half of 2026, and everything else Lilly sells grew just $95 million in 2025.
Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs
02.11.2026 14:20
The market for GLP-1 drugs is forecast to explode. It may be understated still.
Eli Lilly Jumped 6% After Earnings. It’s Up 68% in a Year. Where Does the Target Go Now?
02.11.2026 13:47
Mounjaro and Zepbound just handed Lilly a blowout quarter, but falling realized drug prices and one-time revenue boosts that won't repeat raise real questions about whether the rally holds from here.
Eli Lilly stock surges as cheaper drugs unlock a bigger market
01.11.2026 01:47
Lilly shares hit a record as weight-loss drugs became more accessible.
Eli Lilly Rallies 11% in a Week as Q3 Sales Jump 39%, “Exceeding Our Prior Expectations”
31.10.2026 13:27
Key TakeawaysEli Lilly’s Q3 revenue rose 39% to $24. 4 billion, and Mounjaro and Zepbound brought in about $16.
Eli Lilly Soars 11% in a Week on a $5.5 Billion Guidance Raise: “Beating on the Up”
31.10.2026 09:00
Key TakeawaysEli Lilly shares rose 11% in the week through Oct. 30 to a record close after a third-quarter beat and a $5.
Elon Musk Says Eli Lilly Has ‘Some Banger Drugs Coming Out’ After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech Skepticism
31.10.2026 05:14
Elon Musk praises Eli Lilly’s upcoming drug pipeline as CEO Dave Ricks responds to skepticism about innovation at big biotech companies.
Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3
31.10.2026 05:05
Ark Invest increased its exposure to several widely followed biotechnology stocks during the session.
Viking Therapeutics: A Strong Injection, A Scaled-Back Pill
31.10.2026 04:39
Viking Therapeutics is advancing VK2735, a dual GLP-1/GIP agonist for obesity, with Phase 3 injection results expected in 2027. Read why VKTX stock is a hold.
Eli Lilly Stock Rose Nearly 7% to a Record as It Lifted Its 2026 Sales Forecast to as Much as $92 Billion. Here’s Where the Stock Could Go
30.10.2026 13:02
Key Stats for Eli Lilly StockCurrent Price: $1,373. 70Target Price (Mid): ~$2,340Street Target: ~$1,337Potential Total Return: ~70%Annualized IRR: ~14% / yearWhat Happened?Eli Lilly (LLY:NYSE) closed at a record $1,373.
Eli Lilly’s tirzepatide outperforms big pharma companies in Q3
30.10.2026 12:16
Sales for Eli Lilly’s Mounjaro and Zepbound topped $16bn, exceeding total revenue for many big pharma players.
AbbVie Is Up 10% in a Month to a 52-Week High: Is There “More Room for Multiple Expansion”?
30.10.2026 12:06
Key TakeawaysAbbVie stock is up in the past month to a new 52-week high, mostly because investors moved out of AI stocks and into big drugmakers led by Eli Lilly. AbbVie’s own news was steady, but a higher valuation did most of the work, and its forward P/E is now well above its five-year average.
Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
30.10.2026 11:50
Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.
What Sent Eli Lilly Stock Higher?
30.10.2026 11:15
For questions about this article or underlying research, email help@trefis.com.
Has The Story Under Johnson & Johnson Stock Run Out?
30.10.2026 10:49
For questions about this article or underlying research, email help@trefis.com.
Argus Research Maintains Buy on Eli Lilly, Raises Price Target to $1550
30.10.2026 09:53
Argus Research analyst Jasper Hellweg maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1300 to $1550.
LLY Stock Hits Record as CEO Says Middle-Income Consumers Are Driving Pharma’s ‘Largest New Category Expansion’
30.10.2026 06:24
Eli Lilly stock hits a record close as CEO David Ricks points to middle-income demand and a historic pharma category expansion.
Eli Lilly: The Bar Just Got Higher
30.10.2026 05:35
Eli Lilly delivered standout 3Q26 results, with 39% revenue growth to $24.4B, driven by Mounjaro and Zepbound franchises. Read why LLY stock is a buy.